Literature DB >> 35341931

Model-informed precision dosing of vancomycin via continuous infusion: a clinical fit-for-purpose evaluation of published PK models.

Astrid Heus1, David W Uster2, Veerle Grootaert3, Nele Vermeulen4, Annemie Somers5, Diana Huis In't Veld6, Sebastian G Wicha2, Pieter A De Cock7.   

Abstract

BACKGROUND: Model-informed precision dosing is an innovative approach used to guide bedside vancomycin dosing. The use of Bayesian software requires suitable and externally validated population pharmacokinetic (popPK) models.
OBJECTIVES: This study aimed to identify suitable popPK models for a priori prediction and a posteriori forecasting of vancomycin in continuous infusion. Additionally, model averaging (MAA) and model selection approach (MSA) were compared with the identified popPK models.
METHODS: Clinical pharmacokinetic data were retrospectively collected from patients receiving continuous vancomycin therapy and admitted to a general ward of three large Belgian hospitals. The predictive performance of the popPK models, identified in a systematic literature search, as well as the MAA/MSA were evaluated for the a priori and a posteriori scenarios using bias, root mean square errors, normalised prediction distribution errors and visual predictive checks.
RESULTS: The predictive performance of 23 popPK models was evaluated based on clinical data from 169 patients and 923 therapeutic drug monitoring samples. Overall, the best predictive performance was found using the Okada et al. model (bias < -0.1 mg/L) followed by the Colin et al. MODEL: The MAA/MSA predicted with a constantly high precision and low inaccuracy and were clinically acceptable in the Bayesian forecasting.
CONCLUSION: This study identified the two-compartmental models of Okada et al. and Colin et al. as most suitable for non-ICU patients to forecast individual exposure profiles after continuous vancomycin infusion. The MAA/MSA performed equally as well as the individual popPK models; therefore, both approaches could be used in clinical practice to guide dosing decisions.
Copyright © 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

Entities:  

Keywords:  Bayesian forecasting; Model averaging; Population pharmacokinetics; Precision dosing; Therapeutic drug monitoring; Vancomycin

Mesh:

Substances:

Year:  2022        PMID: 35341931     DOI: 10.1016/j.ijantimicag.2022.106579

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  2 in total

1.  Clinical Efficacy and Safety of Vancomycin Continuous Infusion in Patients Treated at Home in an Outpatient Parenteral Antimicrobial Therapy Program.

Authors:  Lore Thijs; Charlotte Quintens; Lotte Vander Elst; Paul De Munter; Melissa Depypere; Willem-Jan Metsemakers; Georges Vles; Astrid Liesenborghs; Jens Neefs; Willy E Peetermans; Isabel Spriet
Journal:  Antibiotics (Basel)       Date:  2022-05-23

2.  Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults.

Authors:  Heleen Gastmans; Erwin Dreesen; Sebastian G Wicha; Nada Dia; Ellen Spreuwers; Annabel Dompas; Karel Allegaert; Stefanie Desmet; Katrien Lagrou; Willy E Peetermans; Yves Debaveye; Isabel Spriet; Matthias Gijsen
Journal:  Pharmaceutics       Date:  2022-07-13       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.